XERF in Daegu: what faces does it suit? — The place of radiofrequency that works area by area
People who come asking for XERF have usually heard “it can be done without anaesthesia” or “it works around the eyes too.” Both relate to XERF’s design, but that doesn’t mean “it suits everyone.” I’ve set out the faces where XERF comes first, the faces where another approach comes first, and what the three studies actually showed.
The short answer
XERF is Lutronic’s monopolar radiofrequency device that uses two frequencies, 6.78 MHz and 2 MHz, and swaps tips of different areas by region. We consider it first for faces where narrow spots such as around the eyes · mouth need separate settings from the cheeks · jawline, and when you want to reduce the burden of anaesthesia. There are three human studies of 20 · 39 · 16 people, all without control groups, and pain without anaesthesia averaged in the 4s on a 10-point scale. Miso Clinic in Daegu (4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, +82-53-428-2700) has XERF and makes it the rule to choose tip and frequency to fit the area and skin thickness (clinical judgement).
What kind of device is XERF?
XERF is Lutronic’s monopolar radiofrequency device. Its design features two frequencies and four tips of different sizes swapped to fit the area.
| Item | Detail |
|---|---|
| Method | Monopolar radiofrequency |
| Frequency | 6.78 MHz + 2 MHz |
| Handpiece i05 | 5×10 mm · 400 shots |
| Handpiece i10 | 10×10 mm · 300 shots |
| Handpiece E40 | 20×20 mm · 600 shots |
| Handpiece E60 | 20×30 mm · 600 shots |
| Korean approval category | General-purpose electrosurgical unit |
In a study of the heat distribution of the two frequencies, 2 MHz heated broadly and deeply in the fat layer, while 6.78 MHz heated locally along the fibrous septa. But it was a computer simulation and pig-tissue study, and many of the authors are affiliated with the manufacturer, so it has not been confirmed as is in human faces (Ko 2025).
Which faces do we consider XERF for first?
Below are the cases where Miso Clinic puts XERF first (clinical judgement). There is no comparative study showing XERF is better than other devices for these faces.
- Faces needing area-by-area settings — small tips for the eye · mouth area, switching to large tips for the cheeks · jawline
- Faces where sagging around the brows · eyelids is also a concern — there is a place for the small tips
- When you want to reduce the burden of anaesthesia — all three studies were done without anaesthesia
- When sagging below the cheeks · along the jawline has begun and you need to return to your day the same day
There is one human study comparing tip size alone (Yang 2024, 31 people split-face, not XERF). The difference between the two tips was not statistically significant (p=0.845). So the reason for swapping tips is even contact in that area rather than size of effect (clinical judgement). The eye area is written up separately in Eye-area XERF in Daegu.
Which faces is XERF not the first choice for?
| In this case | Reason | What we look at first |
|---|---|---|
| Faces with hollow cheeks · temples | Tightening with heat can make them look more hollow | Fillers — Lifting a face with hollow cheeks |
| Thin, dull skin without sagging | It is often a matter of dermal material | Boosters — Lifting thin skin: what to watch for |
| Sagging loose enough for the skin to fold | It is beyond the range of non-invasive RF | Surgical consultation |
| Aiming to reduce fat | XERF has no approved indication for fat reduction | Check layer thickness first |
| Implanted electronic devices such as a pacemaker | With monopolar, current passes through the body | We do not treat |
| Metal implants · irreversible fillers at the treatment area | Heat distribution can change | Avoid the area or adjust the setting |
What did the three studies show?
| Study | Subjects · treatment | Main results | Limitations |
|---|---|---|---|
| Hwang 2025 Medical Lasers | 20 people · 1 session · 12 weeks | Pain VAS 4–5 without anaesthesia, no adverse events | No control group |
| Weiss 2026 Cureus | 39 people · 2 sessions (4 weeks apart) · 90 days | GAIS improvement 30 days 84.6% → 90 days 92.3%, mean pain 4.2/10, mean 568.8 shots per session | No control group · unblinded · manufacturer-supported |
| Erlich 2026 Lasers Med Sci | 16 women, retrospective · 1 session · 3 months | Pain 4.31/10, brow · eyelid 3D measurement +1.11–1.44 mm | Retrospective · no control group |
None of the three has a control group. The improvement rate in the larger 39-person study was rated by the principal investigator who performed the treatment, and the manufacturer supported the device and study. The authors of the Erlich study wrote directly that they could not conclude it was better than single-frequency devices. So these numbers should be read not as “it goes up this much” but as “this was observed under these conditions.”
What do approval and the US 510(k) mean?
XERF’s Korean approval category is general-purpose electrosurgical unit. In the US it received 510(k) clearance (K251327) in August 2025, with the intended use of electrocoagulation · haemostasis, and no clinical trial was submitted. It helps to know that “FDA-registered device” doesn’t mean “the FDA recognised a lifting effect.”
The “general-purpose electrosurgical unit association-2024-16-054” seen on promotional material is a medical advertising pre-review mark, not an approval number. How to read approval information is set out in Approval numbers and advertising review numbers.
Does it hurt, and how do we look at adverse events?
All XERF studies were done without anaesthesia, and pain averaged in the 4s on a 10-point scale (Weiss 2026 4.2, Erlich 2026 4.31). In the Erlich study, 38% scored 3 or below, 50% 4–6, and 12% 7 or above. The accurate expression is not “it doesn’t hurt” but “for most it was bearable without anaesthesia.”
If pain is strong, Miso Clinic adjusts the area and settings, and doesn’t use anaesthesia that completely blocks the pain signal (clinical judgement). Fat atrophy after radiofrequency has been reported at 1–4 months in about 4 per 10,000 treatments, and it has been pointed out that strong anaesthesia masks that signal (Narins 2006). More detail is in XERF pain and XERF side effects.
When are results judged?
The tightness right after is immediate collagen contraction and soon settles. In the 39-person study the share judged improved rose over time, from 84.6% at 30 days to 92.3% at 90 days (Weiss 2026, unblinded). In another radiofrequency study, clinical assessment was not significant at 4 weeks and significant at 12 (Cosmetics 2024).
So we judge 2–3 months later. The last observations in XERF studies were at 90 days · 3 months, so XERF data can’t speak to duration beyond that. If you’re weighing it against Density, see Density or XERF: which to choose?.
XERF in Daegu: frequently asked questions
What faces does XERF suit?
We consider it first for faces where the eye · mouth area needs separate settings from the cheeks · jawline, and when you want to reduce the burden of anaesthesia. If hollow cheeks or thin skin is the main concern, another approach comes first. This is clinical judgement.
Has XERF’s effect been confirmed by research?
There are three human studies of 20 · 39 · 16 people, all without control groups. The 92.3% judged improved at 90 days in the 39-person study is an unblinded practitioner assessment in a manufacturer-supported study.
Is XERF done without anaesthesia?
All three studies were done without anaesthesia, and pain averaged in the 4s on a 10-point scale. That doesn’t mean it doesn’t hurt, so Miso Clinic adjusts the area and settings according to pain.
Is XERF FDA-approved?
It received US 510(k) K251327, but the intended use is electrocoagulation · haemostasis and no clinical trial was submitted. It doesn’t mean a lifting effect was recognised.
When can XERF results be judged?
The tightness right after soon settles, and we judge 2–3 months later. The last observations in XERF studies were at 90 days · 3 months.
Where can I get a XERF consultation in Daegu?
Miso Clinic in Daegu is at 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, in front of Exit 1 of Kyungpook National University Hospital Station. +82-53-428-2700; weekdays 11:00–19:00 · Saturday 10:00–16:00 (no lunch break); closed Sundays · public holidays.
Clinical columns to read next
- XERF lifting in Daegu: which skin does it suit? — a map of 12 XERF columns
- Lifting in Daegu: which device to choose
- Density or XERF: which to choose
- Density in Daegu: which faces does it suit?
- How ultrasound (HIFU) and RF differ
- Men’s lifting in Daegu: how it differs from data on women
- XERF treatment guide in Daegu
- XERF effector tips: what differs?
Product reference
Related material: XERF product reference
Clinic
This column was written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu. The treatment criteria and injection design are written exactly as we actually use them.
| Medical Director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu (Exit 1, Kyungpook National University Hospital Station) · tower parking in the building |
| Phone | 053-428-2700 |
| KakaoTalk consultation | Miso Clinic Daegu channel |
| KakaoTalk channel | Add the channel |
| Opening hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Clinical column | See all columns |
| Reference library | All booster and lifting device references |
References
- XERF specifications — Lutronic published material: monopolar, 6.78 MHz + 2 MHz, handpieces i05 (5×10 mm · 400 shots) · i10 (10×10 mm · 300 shots) · E40 (20×20 mm · 600 shots) · E60 (20×30 mm · 600 shots). Korean approval classification: general-purpose electrosurgical unit; advertising review “General-purpose electrosurgical unit association-2024-16-054”.
- Heating by XERF frequency — Ko K et al., Lasers Med Sci 2025, PMID 41315066. Computer simulation · pig tissue. 2 MHz heated broadly and deeply in the fat layer; 6.78 MHz heated locally along the fibrous septa. Many authors are affiliated with the manufacturer, and it is not a human study.
- Three human studies of XERF — Hwang JK, Medical Lasers 2025;14(1):23–30 (20 people · one session · 12 weeks) · Weiss RA et al., Cureus 2026;18(3):e104546, PMID 41930066 (39 people · two sessions · 90 days, manufacturer-supported) · Erlich G et al., Lasers Med Sci 2026;41(1), PMID 42611100 (retrospective 16 people · one session · 3 months). None of the three had a control group.
- Split-face trial of electrode size — Yang YS et al., J Clin Aesthet Dermatol 2024. 31 people, 3 cm² vs 4 cm² tip. The comparison between the two tips was p=0.845, not significant; the p < 0.001 in the paper is the before-after comparison. Not a Density · XERF study.
- XERF’s US 510(k) — FDA K251327 (2025-08-11). Intended use is electrocoagulation · haemostasis; no clinical trial was submitted. The Korean approval category is general-purpose electrosurgical unit.
- Fat atrophy — Narins RS et al., Dermatol Surg 2006;32:115–124. Appears at 1–4 months (average 2 months), about 4 per 10,000 treatments. Notes that strong anaesthesia blocks pain feedback.
- Timeline of RF results — Cosmetics 2024;11(3):71 (20 Korean women: clinical assessment not significant at 4 weeks · significant at 12 · 24 weeks; device-measured elasticity from 4 weeks) · Weiss 2026 (84.6% at 30 days → 92.3% at 90 days) · Fitzpatrick 2003 and Edwards AF et al., Dermatol Surg 2013;39:104–110 (peak at 4–6 months). None had a control group.
- Fat-reduction indication and clinical submission — US 510(k) K180709 (a body device) included body fat · circumference reduction in its indication and submitted 2 clinical studies. XERF K251327 has no such indication and submitted no clinical data.
- Korean medical advertising law — Medical Service Act Article 56(2), which prohibits testimonial advertising, comparison with other medical institutions and superlative claims.
- Miso Clinic clinical guidelines — criteria for indications, design by area, pre-treatment explanation and consent. The source of sentences marked “clinical judgement” in this column.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.